JP2024546138A - トリプタミンプロドラッグ - Google Patents

トリプタミンプロドラッグ Download PDF

Info

Publication number
JP2024546138A
JP2024546138A JP2024535372A JP2024535372A JP2024546138A JP 2024546138 A JP2024546138 A JP 2024546138A JP 2024535372 A JP2024535372 A JP 2024535372A JP 2024535372 A JP2024535372 A JP 2024535372A JP 2024546138 A JP2024546138 A JP 2024546138A
Authority
JP
Japan
Prior art keywords
alkyl
compound
branched
co2h
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535372A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023108260A5 (https=
JP2024546138A5 (https=
Inventor
ネイサン・ブライソン
Original Assignee
レユニオン ニューロサイエンス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レユニオン ニューロサイエンス，インコーポレイテッド filed Critical レユニオン ニューロサイエンス，インコーポレイテッド
Publication of JP2024546138A publication Critical patent/JP2024546138A/ja
Publication of JPWO2023108260A5 publication Critical patent/JPWO2023108260A5/ja
Publication of JP2024546138A5 publication Critical patent/JP2024546138A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024535372A 2021-12-14 2022-12-08 トリプタミンプロドラッグ Pending JP2024546138A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289501P 2021-12-14 2021-12-14
US63/289,501 2021-12-14
PCT/CA2022/051797 WO2023108260A1 (en) 2021-12-14 2022-12-08 Tryptamine prodrugs

Publications (3)

Publication Number Publication Date
JP2024546138A true JP2024546138A (ja) 2024-12-17
JPWO2023108260A5 JPWO2023108260A5 (https=) 2025-12-24
JP2024546138A5 JP2024546138A5 (https=) 2025-12-24

Family

ID=86775179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535372A Pending JP2024546138A (ja) 2021-12-14 2022-12-08 トリプタミンプロドラッグ

Country Status (6)

Country Link
US (1) US20250051278A1 (https=)
EP (1) EP4448489A4 (https=)
JP (1) JP2024546138A (https=)
CN (1) CN118679146A (https=)
CA (1) CA3240633A1 (https=)
WO (1) WO2023108260A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551981A1 (en) * 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses

Also Published As

Publication number Publication date
US20250051278A1 (en) 2025-02-13
CN118679146A (zh) 2024-09-20
CA3240633A1 (en) 2023-06-22
WO2023108260A1 (en) 2023-06-22
EP4448489A4 (en) 2025-12-31
EP4448489A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
JP7702654B2 (ja) トリプタミンプロドラッグ
JP2024546138A (ja) トリプタミンプロドラッグ
JP2024514703A (ja) ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用
WO2005040135A1 (ja) 抗ストレス薬およびその医薬用途
ES2308127T3 (es) Nuevos derivados de acidos dicarboxilicos.
JP4832897B2 (ja) エステル誘導体及びその医薬用途
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
HK40114112A (zh) 色胺前药
JP5291721B2 (ja) 置換３−ヒドロキシピリジン及びその医薬組成物
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
HK40114252A (zh) 色胺前药
HK40114605A (zh) 色胺前药
HK40091294A (zh) 色胺前药
HK40091294B (zh) 色胺前药
WO2011058943A1 (ja) Ｍｃｈ ｒ１アンタゴニスト活性を有する化合物とｎｐｙ ｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
WO1997024030A1 (en) Pyrrolidine derivatives
WO1994002452A1 (fr) Derive du benzene
JP2004210733A (ja) アリールスルファマート誘導体
JPWO1994018191A1 (ja) 新規なアミン誘導体
WO1994006772A1 (fr) Derive de 3-azabicyclo[3.2.1]octane, procede de production et utilisation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250922

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251208